-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

617A.O1.6 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Minimal Residual Disease and Therapy Response Clinically Relevant Abstract

Symposia: Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, clinical trials, Acute Myeloid Malignancies, AML, Clinical Practice (Health Services and Quality), Clinical Research, Diseases, Therapies, Myeloid Malignancies, Minimal Residual Disease
Sunday, December 10, 2023: 9:30 AM-11:00 AM
Marriott Grand Ballroom 8-9 (Marriott Marquis San Diego Marina)
Moderators:
Jad Othman, MBBS, and Rong He, MD, Mayo Clinic
Disclosures:
He: Kura Oncology, Inc: Consultancy.
9:30 AM

Corentin Orvain1*, Sarah Bertoli2*, Pierre Peterlin3*, Yohan Desbrosses4*, Pierre-Yves Dumas, MD, PhD5*, Alexandre Iat, MD6*, Marie Anne Hospital7*, Martin Carre, MD8*, Emmanuelle Tavernier, MD9*, Anne Bouvier10*, Audrey Bidet, MD11*, Sylvie Tondeur12*, Florian Renosi13*, Eric Delabesse, MD, PhD14*, Arnaud Pigneux, MD, PhD5*, Hunault-Berger Mathilde15* and Christian Recher, MD16*

1Hematology Department, Angers University Hospital, Angers, France
2IUCT-Oncopole, Hematology Department, CHU de Toulouse - Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France
3Hematology Department, Hôpital Hotel Dieu, NANTES CEDEX 1, France
4Besancon University Hospital, BESANCON, FRA
5Hôpital Haut-Lévèque, Hematology Department, CHU Bordeaux, Pessac, France
6Nice University Hospital, NICE, AL, FRA
7Hematology Department, Institut Paoli-Calmettes, Marseille, France
8Clinical Hematology Department, CHU Grenoble Alpes - Université Grenoble Alpes, Grenoble, France
9Institut De Cancérologie De La Loire, Saint Priest En Jarez, FRA
10Angers University Hospital, ANGERS, AL, FRA
11Laboratoire d’Hématologie Biologique, CHU Bordeaux, Bordeaux, France
12Grenoble Alpes University Hospital, Grenoble, FRA
13Université de Franche-Comté, CHU Besançon, EFS, INSERM, UMR RIGHT, BESANCON, France
14IUCT-Oncopole, Hematology Laboratory, CHU de Toulouse - Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France
15Angers University Hospital, Angers, ML, France
16ICUT oncopole, Toulouse, FRA

9:45 AM

Martina Pigazzi, PhD1,2*, Maddalena Benetton, PhD1*, Pietro Merli, MD3*, Rosanna Cuccurullo, MD4*, Katia Polato1*, Pamela Scarparo, PhD5*, Manuela Tumino, MD6*, Simone Cesaro7*, Rosa Maria Mura, MD8*, Concetta Micalizzi, MD9*, Claudia Tregnago, PhD1*, Carmelo Rizzari, MD10*, Marco Zecca, MD11*, Barbara Buldini, MD, PhD12 and Franco Locatelli, MD, PhD13

1Department of Women's and Children's Health, Onco-hematology lab and clinic, University of Padova, Padova, Italy
2Foundation Istituto Ricerca Pediatrica (IRP), Padova, Italy
3Department of Pediatric Hematology and Oncology, IRCCS Bambino Gesù Children’s Hospital, Catholic University of the Sacred Heart, Rome, Italy
4Pediatric Hemato Oncology, Pausillipon Hospital, Naples, Italy
5Pediatric Hematology, Oncology and Stem Cell Transplant Division, Maternal and Child Health Department, University of Padova, Padova, Italy
6Department of Women’s and Children’s Health, Onco-hematology lab and clinic, University-Hospital of Padova, Padova, Italy
7Pediatric Hematology-Oncology, Azienda Ospedaliera Universitaria Integrata, Verona, Italy
8Department of Paediatric Oncohaematology, Microcitemico Hospital, Cagliari, Cagliari, ITA
9IRCCS Istituto Giannina Gaslini, Department of Paediatric Haematology and Oncology, Genova, Italy
10Pediatric Hematology-Oncology Unit, Department of Pediatrics, University of Milano-Bicocca, MBBM Foundation c/o ASST Monza, Milan, Italy
11Pediatric Hematology-Oncology,, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
12Department of Pediatric Hematology and Oncology, University of Padova, Padua, Italy
13Department of Pediatric Hematology/Oncology, Cell and Gene Therapy, IRCCS Bambino Gesù Children’s Hospital, Catholic University of the Sacred Heart, Rome, Italy

10:00 AM

Chong Chyn Chua, MBBS, FRACP, FRCPA, PhD1,2,3, Natasha Anstee, PhD2*, Christoffer Flensburg, PhD2,4*, Charis Teh, MPH, PhD2,4*, Adam Ivey, PhD1*, Noorul Amin, PhD2*, Rachel Thijssen, PhD5,6,7*, Stefan K. Bohlander8*, Purvi M. Kakadia, PhD8*, Zhen Xu, PhD2,4*, Chun Yew Fong, MBBS, FRACP, FRCPA, PhD9, Stephen Ting, MBBS, FRACP, FRCPA, PhD10, Sun Loo, MBBS2,3,11, Ing Soo Tiong, FRACP, FRCPA, MPhil1,12, Daniel Gray, PhD2*, Shaun Fleming13*, Nadia Davidson, BE(Hons.), BSc(Hons.), PhD2*, Andrew W. Roberts, MBBS, PhD14,15,16, Ian Majewski, PhD2,4*, Andrew H. Wei, MBBS, PhD14,16,17 and Fiona C. Brown, PhD14*

1The Alfred Hospital and Monash University, Melbourne, VIC, Australia
2The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia
3Northern Hospital, Epping, VIC, Australia
4Department of Medical Biology, the University of Melbourne, Melbourne, VIC, Australia
5The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia
6Cancer Centre Amsterdam, Amsterdam, Netherlands
7Amsterdam UMC, Amsterdam, Netherlands
8Leukaemia and Blood Cancer Research Unit, Department of Molecular Medicine and Pathology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
9Austin Hospital, Heidelberg, Australia
10Department of Haematology, Eastern Health and Monash University, Melbourne, Australia
11Department of Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, VIC, Australia
12Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
13Alfred Health, Melbourne, Australia
14The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia
15The Royal Melbourne Hospital, Melbourne, VIC, Australia
16Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia
17Peter Maccallum Cancer Centre, Melbourne, VIC, Australia

10:15 AM

Gege Gui, ScM1,2, Laura W Dillon, PhD1*, Niveditha Ravindra, MD1*, Pranay S. Hegde, BS1*, Georgia Andrew, BSc1*, Devdeep Mukherjee, PhD1*, Zoe Wong, BS1*, Jeffery J. Auletta, MD3,4, Firas El Chaer, MD5, Evan C. Chen, MD6, Yi-Bin Chen, MD, MS7, Adam Corner, PhD8*, Steven M. Devine, MD9, Sunil G. Iyer, MD10, Antonio M. Jimenez Jimenez, MD, MSc11*, Marcos de Lima, MD12*, Mark R. Litzow, MD13, Partow Kebriaei, MD14, Wael Saber, MD, MS4,15, Stephen R. Spellman, MBS4,16*, Scott L. Zeger, PhD2*, Kristin M. Page, MD4,15 and Christopher S. Hourigan, DM, DPhil1,17

1Laboratory of Myeloid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, MD
2Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
3Hematology/Oncology/Bone Marrow Transplant and Infectious Diseases, Nationwide Children's Hospital, Columbus, OH
4Center for International Blood and Marrow Transplant Research, Minneapolis, MN
5Department of Medicine, Division of Hematology and Oncology, University of Virginia Comprehensive Cancer Center, Charlottesville, VA
6Dana-Farber Cancer Institute, Boston, MA
7Massachusetts General Hospital, Boston, MA
8Bio-Rad Laboratories, Pleasanton, CA
9CIBMTR® (Center for International Blood and Marrow Transplant Research), National Marrow Donor Program/Be The Match, Minneapolis, MN
10Division of Hematology and Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY
11Sylvester Comprehensive Cancer Center, Miller School of Medicine, Miami, FL
12Division of Hematology, The Ohio State University Wexner Medical Center, Columbus, OH
13Division of Hematology, Mayo Clinic, Rochester, MN
14Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
15Medical College of Wisconsin, Milwaukee, WI
16National Marrow Donor Program, Minneapolis, MN
17Myeloid Malignancies Program, National Institutes of Health, Bethesda, MD

10:30 AM

Jad Othman, MBBS1,2,3, Nicola Potter, PhD1*, Adam Ivey4*, Jelena Jovanovic, PhD5*, Sylvie D Freeman6, Amanda Gilkes7*, Ian Thomas8*, Sean Johnson8*, Joanna Canham9*, Jamie Cavenagh10*, Panos Kottaridis11*, Claire Arnold12*, Ulrik Malthe Overgaard13*, Mike Dennis, MD, MRCP, FRCPath14, Charlotte Wilhelm-Benartzi7*, Richard Dillon, PhD, MRCP, FRCPath1,2* and Nigel Russell15

1Department of Medical and Molecular Genetics, King's College London, London, United Kingdom
2Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
3Faculty of Medicine and Health, University of Sydney, Sydney, Australia
4Alfred Health, Melbourne, AUS
5King’s College London, London, United Kingdom
6Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom
7Cardiff University, Cardiff, GBR
8Cardiff University, Cardiff, United Kingdom
9Cardiff University, Cardiff, WAL, GBR
10Department of Haemato-Oncology, St Bartholomew's Hospital, Barts Health NHS Trust, London, GBR
11University College London Hospital NHS Foundation Trust, London, GBR
12Belfast City Hospital, Belfast, GBR
13Department of Hematology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
14The Christie, Manchester, GBR
15Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom

10:45 AM

Jacqueline A. Cook, BS*, Loren Lott*, Jenna Perry*, Arun Nalla, PhD*, Dongbin Xu, PhD*, Chad A. Hudson, MD, PhD, Denise A. Wells, MD*, Michael R. Loken, PhD* and Andrew J. Menssen, PhD

Hematologics, Inc., Seattle, WA

*signifies non-member of ASH